pre-IPO PHARMA

COMPANY OVERVIEW

PsiOxus aims to be the world’s leading cancer gene therapy company, delivering medicines of value to patients with cancer. Our work is product and platform based with a focus on discovering and developing gene-based immuno-oncology therapies for the treatment of solid tumors. The T-SIGn gene therapy platform is based on the company's oncolytic virus, enadenotucirev, which has properties that allow systemic IV delivery and payload capacity to deliver genes as a viral vector.


LOCATION

  • Abingdon, Oxfordshire, UK
  • Plymouth Meeting, PA, USA

  • THERAPEUTIC AREAS

  • Oncology

  • WEBSITE

    http://psioxus.com


    CAREER WEBSITE

    http://psioxus.com/recruitment-opportunities/


    SOCIAL MEDIA


    INVESTORS

    invesco-perpetual ip-group lundbeckfonden lundbeckfonden mercia-technologies sr-one woodford-investment-management


    PRESS RELEASES


    Aug 11, 2022

    PsiOxus Therapeutics Appoints Howard Davis, Ph.D. as Chief Executive Officer


    Apr 7, 2021

    PsiOxus Therapeutics Updates Agreement with Bristol Myers Squibb to Advance their Clinical Stage Immuno-Oncology Collaboration


    Mar 5, 2020

    PsiOxus Therapeutics Announces Clinical Trial with Third Cancer Gene Therapy Treatment and Appointment of New Chief Medical Officer


    Mar 5, 2020

    PsiOxus Therapeutics Announces Clinical Trial with Third Cancer Gene Therapy Treatment and Appointment of New Chief Medical Officer


    Nov 26, 2018


    For More Press Releases


    Google Analytics Alternative